Eyepoint Pharmaceuticals (EYPT) News Today

EyePoint Pharmaceuticals (NASDAQ: EYPT) is under significant pressure after its lead candidate, DURAVYU, failed to meet the primary endpoint in the Phase 3 LUCIA trial. The setback has sharply weakened the company’s clinical and commercial outlook, while analysts remain cautious.

• Positive Sentiment: High call-option activity indicates that some traders are positioning for a potential rebound or are speculating on substantial volatility in EYPT shares. Stock Traders Purchase Large Volume of Call Options on Eyepoint Pharmaceuticals
• Positive Sentiment: RBC identified EyePoint’s diabetic macular edema study readout as a possible future catalyst, although the company must overcome the recent wAMD trial disappointment. EyePoint's DME Study Readout a Catalyst
• Neutral Sentiment: HC Wainwright maintained a Neutral rating. It reduced its Q3 2026 EPS estimate to a loss of $0.85 from $0.60 and cut its FY2026 estimate to a loss of $3.40 from $3.15, but projects a $0.45-per-share profit for Q3 2027. HC Wainwright estimates
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities claims related to the LUCIA trial failure and the resulting one-session loss of nearly 80% in EYPT’s value. The investigation adds legal and reputational risk. Levi & Korsinsky investigation
• Negative Sentiment: Analyst sentiment has deteriorated: JPMorgan assigned an Underweight rating, while Jefferies and Guggenheim downgraded the stock. Mizuho and HC Wainwright remain Neutral, and Laidlaw reaffirmed Hold ratings, signaling limited near-term confidence.